

A. Clinical Trials

Sl. No	Title	CRO	Sponsor	Status
01	Multicenter, Prospective, Open-Label, Single-Arm trial to evaluate the pharmacokinetics, efficacy, and safety of Human Plasma derived Fibrinogen (FIB Grifols) in Patients with Congenital Afibrinogenaemia	Max Neeman Medical International, New Delhi	INSTITUTO GRIFOLS, S.A. POLÍGONO LEVANTE, C/CAN GUASC 2, 08150 PARETS DEL VALLÈS, BARCELONA, SPAIN	Completed
02	Prospective, open-label, uncontrolled, Phase III study to assess the efficacy, safety, and pharmacokinetics of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in paediatric subjects with congenital fibrinogen deficiency	Max Neeman Medical International, New Delhi	OCTAPHARMA AG SEIDENSTRASSE 2 8853 LACHEN SWITZERLAND	Completed
3	An Open-Label, Baseline-Controlled Study in Children and Adolescents Aged 6 Months – 17 Years to Assess the Immunogenicity, Reactogenicity and Safety of a Quadrivalent Influenza Vaccine in India.	JSS & IQVIA India PVT Ltd	Abbott, India Ltd	Completed
4	A randomized, two arm, Observer-blind, parallel-group, active-controlled, multi-center clinical study to evaluate the immunogenicity and safety of Influvac Tetra compared to VaxiFlu-4 in healthy adult and elderly subjects (Protocol Number: INFQ3005)	JSS & IQVIA India PVT Ltd	Abbott, India Ltd	Completed
5	Low-birthweight infant feeding exploration	Bill & Melinda Gates Foundation	JNMC, Belgaum	Completed